Foreign-Trade Zone (FTZ) 22-Chicago, Illinois, Notification of Proposed Production Activity, AbbVie, Inc. (Pharmaceutical Products), North Chicago and Lake County, Illinois, 7989 [2021-02234]

Download as PDF 7989 Notices Federal Register Vol. 86, No. 21 Wednesday, February 3, 2021 This section of the FEDERAL REGISTER contains documents other than rules or proposed rules that are applicable to the public. Notices of hearings and investigations, committee meetings, agency decisions and rulings, delegations of authority, filing of petitions and applications and agency statements of organization and functions are examples of documents appearing in this section. DEPARTMENT OF COMMERCE Foreign-Trade Zones Board [B–04–2021] jbell on DSKJLSW7X2PROD with NOTICES Foreign-Trade Zone (FTZ) 22— Chicago, Illinois, Notification of Proposed Production Activity, AbbVie, Inc. (Pharmaceutical Products), North Chicago and Lake County, Illinois AbbVie, Inc. (AbbVie) submitted a notification of proposed production activity to the FTZ Board for its facilities in North Chicago and Lake County, Illinois. The notification conforming to the requirements of the regulations of the FTZ Board (15 CFR 400.22) was received on January 27, 2021. AbbVie already has authority to produce pharmaceutical products within Subzone 22S. The current request would add a finished product and a foreign status material to the scope of authority. Pursuant to 15 CFR 400.14(b), additional FTZ authority would be limited to the specific foreignstatus material and specific finished product described in the submitted notification (as described below) and subsequently authorized by the FTZ Board. Production under FTZ procedures could exempt AbbVie from customs duty payments on the foreign-status materials/components used in export production. On its domestic sales, for the foreign-status materials/components noted below and in the existing scope of authority, AbbVie would be able to choose the duty rates during customs entry procedures that applies to IMBRUVICA® tablets (duty-free). AbbVie would be able to avoid duty on foreign-status components which become scrap/waste. Customs duties also could possibly be deferred or reduced on foreign-status production equipment. The material sourced from abroad is Ibrutinib active pharmaceutical VerDate Sep<11>2014 17:21 Feb 02, 2021 Jkt 253001 ingredient (duty rate 6.5%). The request indicates that Ibrutinib is subject to duties under Section 301 of the Trade Act of 1974 (Section 301), depending on the country of origin. The applicable Section 301 decisions require subject merchandise to be admitted to FTZs in privileged foreign status (19 CFR 146.41). Public comment is invited from interested parties. Submissions shall be addressed to the Board’s Executive Secretary and sent to: ftz@trade.gov. The closing period for their receipt is March 15, 2021. A copy of the notification will be available for public inspection in the ‘‘Reading Room’’ section of the Board’s website, which is accessible via www.trade.gov/ftz. For further information, contact Christopher Wedderburn at Chris.Wedderburn@trade.gov. Dated: January 28, 2021. Andrew McGilvray, Executive Secretary. [FR Doc. 2021–02234 Filed 2–2–21; 8:45 am] BILLING CODE 3510–DS–P DEPARTMENT OF COMMERCE International Trade Administration [A–549–833] Citric Acid and Certain Citrate Salts From Thailand: Partial Rescission of Antidumping Duty Administrative Review, 2019–2020 Enforcement and Compliance, International Trade Administration, Department of Commerce. SUMMARY: The Department of Commerce (Commerce) is rescinding the administrative review of the antidumping duty order on citric acid and certain citrate salts (citric acid) from Thailand covering the period of review (POR) July 1, 2019, through June 30, 2020, in part, with respect to Niran (Thailand) Co., Ltd. (Niran), based on a timely withdrawal of the request for review for Niran. DATES: Applicable February 3, 2021. FOR FURTHER INFORMATION CONTACT: Joy Zhang, AD/CVD Operations, Office III, Enforcement and Compliance, International Trade Administration, U.S. Department of Commerce, 1401 Constitution Avenue NW, Washington, DC 20230; telephone: (202) 482–1168. AGENCY: PO 00000 Frm 00001 Fmt 4703 Sfmt 4703 SUPPLEMENTARY INFORMATION: Background On July 1, 2020, Commerce published in the Federal Register a notice of opportunity to request an administrative review of the antidumping duty order on citric acid from Thailand for the period July 1, 2019, through June 30, 2020.1 Based on timely requests from COFCO Biochemical (Thailand) Co., Ltd. (COFCO), Sunshine Biotech International Co., Ltd. (Sunshine), and Archer Daniels Midland Company, Cargill, Incorporated, and Tate & Lyle Ingredients Americas LLC, domestic producers of the subject merchandise and petitioners in the original investigation (collectively, the petitioners),2 on September 3, 2020, in accordance with 751(a)(1) of the Tariff Act of 1930, as amended (the Act), Commerce published in the Federal Register a notice of initiation of administrative review covering COFCO, Sunshine, and Niran.3 On September 17, 2020, Commerce selected COFCO and Sunshine for individual examination and issued the antidumping duty questionnaire to the companies.4 On September 18, 2020, Niran filed a no-shipment certification.5 On October 8, 2020, U.S. Customs and Border Protection (CBP) confirmed that there were no shipments of subject merchandise from Niran during the 1 See Antidumping or Countervailing Duty Order, Finding, or Suspended Investigation; Opportunity to Request Administrative Review, 85 FR 39531 (July 1, 2020). 2 See COFCO’s Letter, ‘‘Citric Acid and Certain Citrate Salts from Thailand: Request for Administrative Review,’’ dated July 28, 2020; see also Sunshine’s Letter, ‘‘Antidumping Duty Investigation of Citric Acid and Certain Citrate Salts from Thailand: Sunshine Biotech Request for Review,’’ dated July 31, 2020; and Petitioners’ Letter, ‘‘Citric Acid and Certain Citrate Salts From Thailand: Petitioners’ Request For Administrative Review,’’ dated July 30, 2020 (the petitioners requested review of COFCO, Sunshine, and Niran). 3 See Initiation of Antidumping and Countervailing Duty Administrative Reviews, 85 FR 172 (September 3, 2020). 4 See Memorandum, ‘‘Antidumping Duty Administrative Review of Citric Acid and Certain Citrate Salts from Thailand; 2019–2020: Selection of Respondents for Individual Examination,’’ dated September 17, 2020. See also Antidumping Questionnaires sent to COFCO and Sunshine, dated September 21, 2020. 5 See Niran’s Letter, ‘‘Citric Acid and Certain Citrate Salts from Thailand: No Shipment Certification,’’ dated September 18, 2020. E:\FR\FM\03FEN1.SGM 03FEN1

Agencies

[Federal Register Volume 86, Number 21 (Wednesday, February 3, 2021)]
[Notices]
[Page 7989]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-02234]


========================================================================
Notices
                                                Federal Register
________________________________________________________________________

This section of the FEDERAL REGISTER contains documents other than rules 
or proposed rules that are applicable to the public. Notices of hearings 
and investigations, committee meetings, agency decisions and rulings, 
delegations of authority, filing of petitions and applications and agency 
statements of organization and functions are examples of documents 
appearing in this section.

========================================================================


Federal Register / Vol. 86, No. 21 / Wednesday, February 3, 2021 / 
Notices

[[Page 7989]]



DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-04-2021]


Foreign-Trade Zone (FTZ) 22--Chicago, Illinois, Notification of 
Proposed Production Activity, AbbVie, Inc. (Pharmaceutical Products), 
North Chicago and Lake County, Illinois

    AbbVie, Inc. (AbbVie) submitted a notification of proposed 
production activity to the FTZ Board for its facilities in North 
Chicago and Lake County, Illinois. The notification conforming to the 
requirements of the regulations of the FTZ Board (15 CFR 400.22) was 
received on January 27, 2021.
    AbbVie already has authority to produce pharmaceutical products 
within Subzone 22S. The current request would add a finished product 
and a foreign status material to the scope of authority. Pursuant to 15 
CFR 400.14(b), additional FTZ authority would be limited to the 
specific foreign-status material and specific finished product 
described in the submitted notification (as described below) and 
subsequently authorized by the FTZ Board.
    Production under FTZ procedures could exempt AbbVie from customs 
duty payments on the foreign-status materials/components used in export 
production. On its domestic sales, for the foreign-status materials/
components noted below and in the existing scope of authority, AbbVie 
would be able to choose the duty rates during customs entry procedures 
that applies to IMBRUVICA[supreg] tablets (duty-free). AbbVie would be 
able to avoid duty on foreign-status components which become scrap/
waste. Customs duties also could possibly be deferred or reduced on 
foreign-status production equipment.
    The material sourced from abroad is Ibrutinib active pharmaceutical 
ingredient (duty rate 6.5%). The request indicates that Ibrutinib is 
subject to duties under Section 301 of the Trade Act of 1974 (Section 
301), depending on the country of origin. The applicable Section 301 
decisions require subject merchandise to be admitted to FTZs in 
privileged foreign status (19 CFR 146.41).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
[email protected]. The closing period for their receipt is March 15, 2021.
    A copy of the notification will be available for public inspection 
in the ``Reading Room'' section of the Board's website, which is 
accessible via www.trade.gov/ftz.
    For further information, contact Christopher Wedderburn at 
[email protected].

    Dated: January 28, 2021.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2021-02234 Filed 2-2-21; 8:45 am]
BILLING CODE 3510-DS-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.